Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction

Aim. To evaluate efficiency of trimetazide MR combined with basic therapy of type 2 diabetes mellitus (DM2) in patients with myocardial infarction (MI). Materials and methods. The study included 106 patients with DM2 who underwent MI. Polycomponent basic therapy supplemented by trimetazideMR at a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E E Novitskaya, G A Baryshnikova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2009
Materias:	diabetes mellitus coronary heart disease trimetazide mr myocardial infarction Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/2d9d731b1a17475d8bd36d66acd209a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d9d731b1a17475d8bd36d66acd209a2
record_format	dspace
spelling	oai:doaj.org-article:2d9d731b1a17475d8bd36d66acd209a22021-11-14T09:00:13ZTherapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction2072-03512072-037810.14341/2072-0351-5400https://doaj.org/article/2d9d731b1a17475d8bd36d66acd209a22009-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5400https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To evaluate efficiency of trimetazide MR combined with basic therapy of type 2 diabetes mellitus (DM2) in patients with myocardial infarction (MI). Materials and methods. The study included 106 patients with DM2 who underwent MI. Polycomponent basic therapy supplemented by trimetazideMR at a daily dose of 70 mg was given to 51 patients. The patients condition 6 and 12 months after treatment was evaluated from the results of echo-CG, 24 hr ECG monitoring, and 6 min walking test. Quality of life was estimated using modified Minnesota questionnaire scores. Results. Trimetazide MR combined with polycomponent basic therapy reduced consumption of nitroglycerine by DM2 patients after myocardial infarction,frequency of ventricular and supraventricular extrasystole in 25.3 and 25.3% of the cases respectively. Episodes of painless myocardial ischemiaoccurred only in 35.6% of the patients. Long-term treatment with trimetazide MR as a component of combined therapy increased injectionfraction in patients with abnormal myocardial contractility (pE E NovitskayaG A BaryshnikovaEndocrinology Research Centrearticlediabetes mellituscoronary heart diseasetrimetazide mrmyocardial infarctionNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 12, Iss 2, Pp 58-61 (2009)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus coronary heart disease trimetazide mr myocardial infarction Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus coronary heart disease trimetazide mr myocardial infarction Nutritional diseases. Deficiency diseases RC620-627 E E Novitskaya G A Baryshnikova Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
description	Aim. To evaluate efficiency of trimetazide MR combined with basic therapy of type 2 diabetes mellitus (DM2) in patients with myocardial infarction (MI). Materials and methods. The study included 106 patients with DM2 who underwent MI. Polycomponent basic therapy supplemented by trimetazideMR at a daily dose of 70 mg was given to 51 patients. The patients condition 6 and 12 months after treatment was evaluated from the results of echo-CG, 24 hr ECG monitoring, and 6 min walking test. Quality of life was estimated using modified Minnesota questionnaire scores. Results. Trimetazide MR combined with polycomponent basic therapy reduced consumption of nitroglycerine by DM2 patients after myocardial infarction,frequency of ventricular and supraventricular extrasystole in 25.3 and 25.3% of the cases respectively. Episodes of painless myocardial ischemiaoccurred only in 35.6% of the patients. Long-term treatment with trimetazide MR as a component of combined therapy increased injectionfraction in patients with abnormal myocardial contractility (p
format	article
author	E E Novitskaya G A Baryshnikova
author_facet	E E Novitskaya G A Baryshnikova
author_sort	E E Novitskaya
title	Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
title_short	Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
title_full	Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
title_fullStr	Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
title_full_unstemmed	Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
title_sort	therapeutic efficiency of trimetazide mr in patients with type 2 diabetes mellitus after myocardial infarction
publisher	Endocrinology Research Centre
publishDate	2009
url	https://doaj.org/article/2d9d731b1a17475d8bd36d66acd209a2
work_keys_str_mv	AT eenovitskaya therapeuticefficiencyoftrimetazidemrinpatientswithtype2diabetesmellitusaftermyocardialinfarction AT gabaryshnikova therapeuticefficiencyoftrimetazidemrinpatientswithtype2diabetesmellitusaftermyocardialinfarction
_version_	1718429638657572864

Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction

Ejemplares similares